Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971372 | 0.90 | AKR1B1 (0.52) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| SCHEMBL20298758 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| 3,5-Dinitrosalicylic Acid SCHEMBL125292 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| SCHEMBL27725215 | 0.83 | GPR35 (0.56) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| SCHEMBL28709886 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| 3,5-Dinitrosalicylic Acid SCHEMBL28323234 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| 3,5-Dinitrosalicylic Acid SCHEMBL29350581 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| SCHEMBL5628816 | 0.81 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| SCHEMBL1877302 | 0.81 | ALDH1A1 (0.62) | ALDH1A1TDP1MAPTALOX15MEN1 | |
| 3,5-Dinitrosalicylic Acid SCHEMBL20550502 | 0.81 | GPR35 (0.59) | ALDH1A1TDP1MAPTALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200864-A1 | METHOD FOR THE SYNTHETIC CLEANING OF PEPTIDES WITHOUT HPLC | Technische Universität Berlin (DE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
| EP-3917927-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3849972-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020052650-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020015717-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-01-23 | — | — | WO | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| EP-1641783-B1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2305254-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20060142340-A1 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-29 | — | — | US | disclosed |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | US | disclosed |
| EP-1641784-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641783-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641782-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638961-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003124-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003121-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000838-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142340-A1 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4 antagonists | HTR4, HTR2B, HTR3B | ALDH1A1 733/4885TDP1 4311/4885MAPT 4015/4885 |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | HTR4, HTR2B, HTR2C | ALDH1A1 1067/4885TDP1 4218/4885MAPT 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.